Gln27→Gluβ2‐Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol

• Published in: Basic & clinical pharmacology & toxicology Vol. 104; no. 5; pp. 374 - 378
• Main Authors: Troncoso, Rodrigo, Moraga, Francisco, Chiong, Mario, Roldán, Juan, Bravo, Roberto, Valenzuela, Rodrigo, Díaz‐Araya, Guillermo, Del Campo, Andrea, Sanhueza, Carlos, Rodriguez, Andrea, Vukasovic, José Luis, Mellado, Rosemarie, Greig, Douglas, Castro, Pablo F., Lavandero, Sergio
• Format: Journal Article
• Language: English; Japanese
• Published: Malden, USA Blackwell Publishing Inc 01-05-2009; Blackwell
• Subjects: Biological and medical sciences; Cardiology. Vascular system; Heart; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Medical sciences; Pharmacology. Drug treatments; Human; Heart failure; Genetic variability; Vasodilator agent; α1-Adrenergic receptor; Cardiovascular disease; β2-Adrenergic receptor; Genotype; Alpha blocking agent; β1-Adrenergic receptor; Heart disease; Carvedilol; Antihypertensive agent; Antagonist; Adrenergic receptor; Beta blocking agent; Polymorphism
• ISSN: 1742-7835; 1742-7843
• DOI: 10.1111/j.1742-7843.2008.00370.x

:  We investigated the clinical response of chronic heart failure patients with β2‐adrenergic receptor Gln27→Glu polymorphism treated for 6 months with carvedilol, a α/β‐antagonist with antioxidant properties. The 6‐min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27→Gluβ2‐adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu27β2‐adrenergic receptor allele. There were however, no significant changes in patients with the Gln27β2‐adrenergic receptor variant.